Published On: Fri, Jun 2nd, 2017

New Analyst Ratings On MEI Pharma, Inc. (MEIP)


Recently stock market analysts have updated their consensus ratings on shares of MEI Pharma, Inc. (MEIP).

Most recent broker ratings

05/24/2017 – Oppenheimer began new coverage on MEI Pharma, Inc. giving the company a “outperform” rating. They now have a USD 6.5 price target on the stock.

08/03/2016 – MEI Pharma, Inc. had its “hold” rating reiterated by analysts at Wedbush. They now have a USD 2 price target on the stock.

10/07/2015 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Cowen.

09/02/2015 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald.

05/13/2015 – MEI Pharma, Inc. was downgraded to “hold” by analysts at Zacks. They now have a USD 6.3 price target on the stock.

03/24/2015 – MEI Pharma, Inc. was downgraded to “neutral” by analysts at Bank of America Merrill Lynch.

03/24/2015 – MEI Pharma, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

03/23/2015 – MEI Pharma, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.

03/23/2015 – MEI Pharma, Inc. was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 2.5 price target on the stock.

09/10/2014 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 16 price target on the stock.

MEI Pharma, Inc. has a 50 day moving average of 1.68 and a 200 day moving average of 1.60. The stock’s market capitalization is 76.12M, it has a 52-week low of 1.23 and a 52-week high of 2.35.

The share price of the company (MEIP) was down -8.00% during the last trading session, with a high of 2.24 and the volume of MEI Pharma, Inc. shares traded was 719533.